Structural insight into the human mitochondrial tRNA purine N1-methyltransferase and ribonuclease P complexes

Stephanie Oerum, Martine Roovers, Robert P. Rambo, Jola Kopec, Henry J. Bailey, Fiona Fitzpatrick, Joseph A. Newman, William G. Newman, Albert Amberger, Johannes Zschocke, Louis Droogmans, Udo Oppermann, and Wyatt W. Yue

From the Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom, the Institut de Recherches Laboris, B-1070 Anderlecht, Belgium, the Diamond Light Source, Harwell Science and Innovation Center, Didcot OX11 0QG, United Kingdom, the Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, University of Manchester, Manchester, M13 9WL, United Kingdom, the Division of Human Genetics, Medical University of Innsbruck, Innsbruck 6020, Austria, the Laboratoire de Microbiologie, Université libre de Bruxelles, 1050 Belgium, and the Botnar Research Centre, NIHR Oxford Biomedical Research Unit, Oxford OX3 7LD, United Kingdom

Edited by Ronald C. Wek

Mitochondrial tRNAs are transcribed as long polycistronic transcripts of precursor tRNAs and undergo post-transcriptional modifications such as endonucleolytic processing and methylation required for their correct structure and function. Among them, 5'-end processing and purine 9 N1-methylation of mitochondrial tRNAs are catalyzed by two proteinaceous complexes with overlapping subunit composition. The Mg2+-dependent RNase P complex for 5'-end cleavage comprises the methyltransferase domain–containing protein RNA methyltransferase 10C, mitochondrial RNase P subunit (TRMT10C/MRPP1), short-chain oxidoreductase hydroxysteroid 17β-dehydrogenase 10C, mitochondrial RNase P subunit (TRMT10C/MRPP1), short-chain oxidoreductase hydroxysteroid 17β-dehydrogenase 10H, and metalloenzyme KIAA0391/MRPP3. An MRPP1–MRPP2 subcomplex also catalyzes the formation of 1-methyladenosine/1-methylguanosine at position 9 using S-adenosyl-l-methionine as methyl donor. However, a lack of structural information has precluded insights into how these complexes methylate and process mitochondrial tRNA. Here, we used a combination of X-ray crystallography, interaction and activity assays, and small angle X-ray scattering (SAXS) to gain structural insight into the two tRNA modification complexes and their components. The MRPP1 N terminus is involved in tRNA binding and monomer–monomer self-interaction, whereas the C-terminal SPOUT domain fold contains key residues for S-adenosyl-l-methionine binding and N1-methylation.

The human mitochondrial genome encodes 22 tRNAs that are required for the translation of 13 mitochondrial DNA-encoded proteins (1). Mitochondrial tRNAs ((mt)tRNAs)5 are transcribed as long polycistronic transcripts of precursor (mt)tRNAs (pre-(mt)tRNAs) (reviewed in Ref. 2). The individual (mt)tRNAs are released from the polycistronic transcripts by 5'– and 3'-end processing and will undergo post-transcriptional modifications (reviewed in Refs. 3 and 4) that contribute to the correct structure and function (4). Around 100 such post-transcriptional modifications have been identified to 16 nucleobases in mammalian (mt)tRNAs (5, 6), including pseudouridylation, methylation, and queuosine formation (7).

Methylation of (mt)tRNA occurs on almost all nitrogen sites of the nucleobases and additionally on a few oxygen and carbon atoms (3). The nitrogen-1 (N1) atom of purine bases at position 9 can be methylated to form 1-methyladenosine (m1A9) or 1-methylguanosine (m1G9) (8). N1-methylation promotes the folding of human (mt)tRNA1–9 into the conventional tRNA L-shape (9, 10) and is probably found in 19 of the 22 (mt)tRNAs

5 The abbreviations used are: (mt)tRNA, mitochondrial tRNA; pre-(mt)tRNA, precursor (mt)tRNA; m1A9, 1-methyladenosine; m1G9, 1-methylguanosine; MTase, methyltransferase; SDR, short-chain dehydrogenase/reductase; MRPP, mitochondrial ribonuclease P protein; NYN, N4BP1 YacP-like nuclease; aa, amino acid(s); MTS, mitochondrial targeting signal; SAM, S-adenosyl-l-methionine; DSF, differential scanning fluorimetry; SIRAS, single-isomorphous replacement with anomalous scattering; PDB, Protein Data Bank; SEC, size-exclusion chromatography; MALDI, multilateral light scattering; SEC-MALS, SEC-coupled MALS; PPR, pentatricopeptide repeat; SAXS, small angle X-ray scattering; NSD, normalized spatial discrepancy; RMSD, root mean square deviation; EMSA, electrophoretic mobility shift assay; 3α-HSD, 3α-hydroxysteroid dehydrogenase; HA, heavy atom; bis-tris, bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane; TCEP, tris(carboxymethyl)phosphine; Mn, molecular weight.

© 2018 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
that contain purine bases at position 9 (8, 11). Across Eukarya and Archaea, formation of both m^1^A and m^1^R is attributed to the Trm1 subfamily of enzymes, belonging to the SPOUT (SpoU and TrmD) superfamily of methyltransferases (MTases) (12, 13). The human genome encodes three Trm10 paralogues with different specificities and subcellular localization: R9MTD2 (TRMT10A gene), R9MTD3 (TRMT10B gene), and R9MTD1 (TRMT10C gene), all representing paralogues to the well-characterized m^1^R Trm10 MTase from Saccharomyces cerevisiae and Schizosaccharomyces pombe (14–16), m^1^A Trm10 MTase from Sulfolobus acidocaldarius, and m^1^R MTase from Thermococcus kodakarenensis (17). Of the human paralogues, TRMT10A and TRMT10B are cytosolic m^1^G MTases (16), whereas R9MTD1/TRMT10C is a mitochondrial m^1^R MTase (16, 18). The importance of the m^1^R modification is underscored by genetic diseases caused by biallelic variants in the genes encoding two of the human paralogue enzymes (19–21).

Uniquely among Trm10 members, the m^1^R MTase activity of human R9MTD1/TRMT10C depends on formation of a binary complex with the 17β-hydroxysteroid dehydrogenase type 10 (HSD17B10, also known as SDR5C1) protein (16). HSD17B10 is a well-characterized mitochondrial enzyme of the short-chain dehydrogenase/reductase (SDR) superfamily (22, 23), involved in the third step of isoleucine β-oxidation using NAD^+^ (24, 25). Additionally, HSD17B10 oxidizes a variety of steroids, alcohols, and short-stranded/branched-saturated fatty acids in vitro (26, 27). The role of HSD17B10 in (mt)tRNA methylation is not understood, because neither its NAD^+^/NADH cofactor-binding site nor SDR catalytic residues are directly required for the m^1^R MTase activity of TRMT10C (16).

The R9MTD1/TRMT10C and HSD17B10 proteins are subunits of the human mitochondrial RNase P complex, where they are known as the mitochondrial RNase P protein 1 (MRPP1) and 2 (MRPP2), respectively (28). The active human mitochondrial RNase P requires an additional protein MRPP3, encoded by the KIAA0391 gene, in complex with MRPP1 and MRPP2. MRPP3 is a Mg^2+^-dependent metalloenzyme of the NNY (N4BP1, YacP-like Nuclease) domain family, and is the catalytic component of the RNase P complex that performs the 5′-end cleavage of pre-(mt)tRNAs by phosphodiester bond hydrolysis (28). Human mitochondrial RNase P is a proteinaceous RNase P complex, with no known homology to cytosolic RNase P ribonucleoproteins. Homologues of all three proteins have since been characterized in Drosophila (29). MRPP3 homologues functioning as single-protein RNase Ps are called PRORPs (proteinaceous RNase Ps) and are also identified in cytoplasm and organelles from Arabidopsis thaliana (30) and mitochondria of Trypanosoma brucei (31). Despite sharing component proteins, the methylation and processing of (mt)tRNA by the respective MRPP1–MRPP2 and MRPP1–MRPP2–MRPP3 complexes are not coupled (16).

To date, the molecular basis of MRPP2 involvement in methylation and processing of (mt)tRNA as well as its interaction with partner proteins is not clear, due in part to a lack of structural information beyond that of human MRPP2 (32–34) and Trm10 homologues from yeast and Archaea with low sequence conservation to MRPP1 (15, 35). In this study, we determined the crystal structure of human MRPP1 catalytic domain to understand its methylation mechanism and specificity. To shed light on the two tRNA-modifying activities that MRPP1 and MRPP2 are involved in, we reconstituted the recombinant MRPP1–MRPP2 complex and studied its interaction with tRNA and MRPP3 using biophysical methods.

**Results**

**MRPP1 harbors an N-terminal dimerization domain and a C-terminal methyltransferase domain**

The 403-amino acid (aa) MRPP1 protein comprises a mitochondrial targeting signal (MTS), an N domain rich in basic residues, a SPOUT-fold methyltransferase (MT) domain, and a ~20-aa extension at the C terminus (C extension) (Fig. 1A). We generated recombinant constructs for MRPP1, including the mature protein (MRPP1^MTS, aa 40–403), N domain alone (MRPP1_N, aa 40–210), and MT domain with/without the C extension (MRPP1^MT+C(D194), aa 195–403; MRPP1^MT+C(D202), aa 203–403).

The oligomeric states of purified proteins were studied by size-exclusion chromatography (SEC) (Fig. 3A and Figs. S3 and S5) using proteins of known molecular weight (Mw) (Fig. S1A). MRPP1^MTS and MRPP1_N eluted at 13.75–13.79 ml (Fig. 3A) and 15.79–15.82 ml (Fig. S3A), giving rise to apparent masses of 87 and 34 kDa, respectively (calculated monomeric mass of 45,374 Da for MRPP1^MTS and 17,825 Da for MRPP1_N, corresponding to a dimer for both constructs. The elution volume (V_e) of MRPP1^MT+C(D194) (17.21–17.25 ml; Fig. S3B) yields an apparent mass of 18 kDa, consistent with a monomer (calculated monomeric mass 27,109 Da for MRPP1^MT+C(D194)). MRPP1^MTS was further assessed using size-exclusion chromatography–coupled multiangle light scattering (SEC-MALS) that determined an apparent mass of 56 ± 1.12 kDa (Fig. 1B).

These data suggest that isolated MRPP1^MTS protein exists as a mixture of monomer and dimer in solution and that dimerization is mediated by the N-terminal region. The yeast and archeal Trm10 counterparts are reported as monomers in solution even with the presence of N-terminal extensions to their MTS domains (15, 35). Like for other Trm10 proteins, the MTase domain of MRPP1 with the C extension exists as a monomer in solution, consistent with dimerization taking place via the N-terminal region.

MRPP1 contains a SPOUT fold MTase domain known to bind the methylation cofactor S-adenosyl-L-methionine (SAM). To confirm that MRPP1 binds SAM, we employed differential scanning fluorimetry (DSF) to determine ligand-induced changes in protein melting temperature (T_m) (Fig. 1C). MRPP1^MTS and MRPP1^MT+C(D194) resulted in dose-dependent 

**T_m** increase in the presence of SAM, reaching a maximal 

**T_m** shift of 6.04 ± 0.09 and 9.75 ± 0.48 °C, respectively, at 7.5 mM SAM. The 

**T_m** of MRPP1_N, however, was unaffected in the presence of SAM. This confirms that MRPP1 binds SAM within the expected SPOUT MTase fold, and not the N domain. The MTase domain of MRPP1 can also bind SAM homologues, such as the product of methylation S-adenosyl-homocysteine (T_m of 5.00 ± 0.18 °C), and nucleotides, such as 3′-AMP (T_m of 3.65 ± 0.16 °C) (Fig. S1B).
The MRPP1 methyltransferase domain adopts a monomeric SPOUT fold

We next characterized MRPP1 by structural methods to understand its molecular properties. Attempts to crystallize MRPP1_MTS have not been successful, in part due to its tendency to be proteolyzed during the purification procedures. We crystallized MRPP1_MTS (Fig. 1A) in the presence of SAM, and single-isomorphous replacement with anomalous scattering (SIRAS) was used to determine a 2.49 Å resolution mercury-derivatized structure. A native data set was solved by molecular replacement to 1.96 Å resolution and used for subsequent model building and refinement (Table 1). In the final model, the C-terminal extension (residues 380–403) were disordered and not visible in the electron density. This structure will be referred to hereafter as MRPP1_MT.

MRPP1_MT displays the canonical SPOUT α/β fold, consisting of a central 6-stranded β-sheet (β1–β6) flanked on both sides by α-helices (α1–α6) (Fig. 2A). The SPOUT fold is characterized by the trefoil knot near the C terminus, forming a deep crevice that accommodates the active site. The closest structural homologues of MRPP1 (Fig. S1C), based on a DALI search, are from Trm10 family members that include human TRMT10A (PDB entry 4FMW, Z-score 26.4, Cα RMSD of 1.5 Å, 26% sequence identity), Trm10 from S. cerevisiae (4JWJ, 23.6, 1.9 Å 23%), and Trm10 from S. acidocaldarius (5A7T, 14.0, 2.5 Å, 16%).

Although MRPP1_MT crystallizes with three molecules in the asymmetric unit (Cα RMSD of 0.204–0.238 Å), PISA intermolecular surface analysis (36) of the three molecules did not reveal interactions that could result in stable, physiologically relevant oligomer formation. Most characterized SPOUT domains are dimers, mediated by helix α5 as the dimerization interface. Like other Trm10 members, helix α5 packs against an additional helix (α6) in our MRPP1_MT structure and hence is sterically blocked from forming the typical SPOUT dimer interface (Fig. S1D). Therefore, our structural observations are consistent with analytical SEC of the isolated MRPP1_MT domain, which elutes as a monomer (Fig. S3B), and with other Trm10 member proteins characterized to date (Trm10 from yeast and Archaea) (15, 35).

**SAM-bound MRPP1 structure reveals active site and substrate binding surface**

Each MRPP1_MT subunit is bound by a SAM molecule (Fig. 2A and Fig. S1E), SAM adopts an L-shaped bent configuration, in a binding pocket close to the trefoil knotted region of the SPOUT fold. The SAM pocket is enclosed by four extended loops highly conserved in sequence (Fig. S2), harboring motifs I (aa 288–294), II (aa 307–323), III (aa 335–338), and IV (aa 350–360) (Fig. 2B). The SAM adenine moiety (N1, N7, and exocyclic N6 atoms) forms main-chain hydrogen bonds to backbone atoms of Ser-322, Thr-321, and Gln-318. The ribose 2′-3′-OH moiety forms a hydrogen bond with Gly-310 backbone amide. The methyl Cβ atom of SAM is accessible through a shaft that opens to an extensive surface of positive charges (Lys-216, Arg-217, Lys-218, Arg-235, Arg-236, Arg-256, Lys-260, Arg-261, Lys-265, Lys-268, Lys-315, Arg-358, Lys-378, and Arg-379), which may assist in substrate tRNA binding.
The crystal structures of m1R MTases, including Trm10 (m1G9) and TrmD (m1G37), feature a conserved aspartate residue suggested to act as the general base to abstract a proton from the N1 atom of guanosine and promote methylation (37). For S. cerevisiae, the corresponding aspartate residue was proposed to act together with other carboxylate-containing residues to promote ionization required for catalysis (37). For adenosine, this residue has been suggested to abstract a proton from the exocyclic N6 atom, forming an imino tautomer (38, 39). In MRPP1, residue Asp-314 is strictly invariant among 150 orthologues and hydrogen-bonds to the backbone amide of Ser-316, Met-317, and the NH$_3$ group of the SAM methionyl moiety (Fig. 2D). The distance of 4 Å between Asp-314 and the transferred methyl carbon (C$_e$) atom of SAM renders it likely to function in proton abstraction. Another active-site residue of MRPP1 strictly invariant across orthologous proteins is Gln-226, located in helix α1 with its side chain pointing toward the active site (Fig. 2E).

**MRPP1 uses multiple regions to interact with MRPP2**

The expression and stability of MRPP1 in vivo depends on MRPP2 (40), implicating a physical complex between MRPP1 and MRPP2 as previously demonstrated (16, 28). When recombinant MRPP1$_{\text{MTS}}$ is applied to analytical SEC with excess MRPP2 (Fig. 3A and Fig. S5), this results in a peak ($V_c = 11.72$ ml) of the complex and two subsequent peaks corresponding to uncomplexed single components ($V_c = 13.48$ ml for MRPP1$_{\text{MTS}}$, $V_c = 13.79$ ml for MRPP2). The complexed proteins retained their ability to bind the cofactor (NADH) and methyl donor (SAM), as shown in a DSF assay (Fig. S1F). Further, when MRPP2 is mixed with either MRPP1$_N$ (Fig. S3A) or MRPP1$_{\text{MTS}194}$ (Fig. S3B), no complex peaks were observed. This suggests that both the N and MT domains of MRPP1 are required for interaction with MRPP2.

We next determined the biophysical and enzymatic activities of the MRPP1$_{\text{MTS}}$–MRPP2 complex, co-expressed using an *Escherichia coli* bicistronic system, such that MRPP1$_{\text{MTS}}$ is His-tagged at the N terminus and MRPP2 is untagged. MRPP2 is co-purified only with His-MRPP1$_{\text{MTS}}$ on affinity chromatography resin, and not with His-MRPP1$_N$ or His-MRPP1$_{\text{MTS}194}$ (Fig. S3C). This agrees with analytical SEC findings that both the N and MT domains of MRPP1 are required for interaction with MRPP2. Co-expression of MRPP1 and MRPP2 also eliminated degradation otherwise observed for MRPP1$_{\text{MTS}}$ when expressed alone (Fig. S3D). SEC-MALS of the MRPP1$_{\text{MTS}}$–MRPP2 complex reveals a mass of 194 ± 1.16 kDa (Fig. 3B), indicating a stoichiometry of 2 MRPP1$_{\text{MTS}}$ monomers and 4 MRPP2 monomers in the complex with an expected mass of 208 kDa.

To map the sequence region(s) of MRPP1 that interacts with MRPP2, we probed an array of serially overlapping 15-mer peptides of the entire MRPP1 sequence, generated using SPOT technology (41), with His-tagged MRPP2 followed by immunoblotting. Seven footprints indicative of putative binding regions (Fig. 3C) are found across both domains of MRPP1, with the strongest binding peptides covering the stretch of aa 100–105 in the N domain (Fig. 3D, region 1). Additional binding
peptides are found between the end of the N domain and start of the MT domains (hereafter referred to as the linker) (region 2), within the MT domain (regions 3–6), and in the C extension (region 7).

When mapped onto the MRPP1203–380 structure, regions 3, 4, and 6 are surface-exposed.

Regions 3 and 4 are closer to the start of the structure and cluster into a patch with region 2 in the linker (Fig. 3E) seven residues away. Region 6 is located in a mobile loop near the end of the structure, and the equivalent region in yeast Trm10s has been shown to play a role in activity (15). In summary, regions from the N domain, MT domain, and C extension of MRPP1 are all involved in interactions with MRPP2, which agrees with the SEC and co-expression data.

The N domain of MRPP1 is involved in tRNA binding

Unlike Trm10s from lower eukaryotes, the m1R9 MTase activity of MRPP1 requires the presence of MRPP2 in a binary complex (16). We first confirmed the binding of tRNA to the MRPP1MTS–MRPP2 complex, but not MRPP1MTS alone (Fig. 4D), indicating that this domain is involved in tRNA binding.

MRPP2 is required for MRPP1 MTase function, but MRPP1 does not inhibit MRPP2 activity

We next measured in vitro tRNA MTase activity using [methyl-3H]SAM and purified tRNAs (pre-(mt)tRNAIle for m1G9 MTase activity and pre-(mt)tRNAVal for m1A9 MTase activity) as substrates. Co-expressed MRPP1MTS–MRPP2 complex, but not MRPP1MTS or MRPP1MT(202) alone, methylates pre-(mt)tRNAIle and pre-(mt)tRNAVal (Fig. 4D). Importantly, both m1G9 and m1A9 MTase activities of the complex are abolished with the D314N or Q226A substitution on MRPP1 (Fig. 4D), confirming the essential catalytic roles of the strictly invariant Asp-314 and Gln-226 residues. Mixtures of MRPP1N + MRPP2 and MRPP1MT + MRPP2 proteins, which did not result in complex formation in SEC (Fig. S3, B and C), also did not exhibit tRNA MTase activity (Fig. 4D).

We also determined whether the presence of MRPP1 would influence the SDR function of MRPP2 within the MRPP1MTS–MRPP2 complex. The in vitro 3α-HSD activity of the complex, measured using the neurosteroid allopregnanolone as MRPP2 substrate, revealed a Vmax similar to that of MRPP2 protein alone (Fig. 4E). Further studies are warranted to determine whether the 2-fold reduced Km (allopregnanolone) of the complex, compared with MRPP2 alone, would indicate enhancement of MRPP2 activity by MRPP1. In summary, MRPP2 is required for methyltransferase activity of MRPP1, but MRPP2

Figure 2. Crystal structure of MRPP1 methyltransferase domain. A, assignment of secondary structure elements (blue, helices a1–6; cyan, strands b1–5) in the cartoon representation of MRPP1 MT domain (MRPP1MT). SAM ligand is shown in sticks. B, the four conserved motifs I–IV (orange) in the Trm10 family, to which MRPP1 belongs, are mapped on the MRPP1MT structure. SAM is shown in sticks. C, schematic representation of residues interacting with SAM. Dashed lines represent hydrogen bonds between residues and the ligand. D, view of the active site highlighting the role and interactions of the strictly conserved Asp-314 with both the ligand SAM and the backbone of residues Ser-316 and Met-317. Hydrogen bonds are indicated as dashed lines, and bonding distances (Å) are shown. E, surface representation of the active site highlighting the strictly conserved residue Gln-226, with its side chain pointing toward the SAM ligand.
within the MRPP1–MRPP2 complex is still fully functional as an SDR.

**MRPP1–MRPP2 complex interacts with MRPP3 in the presence of tRNA**

The MRPP1–MRPP2 complex interacts with the Mg\(^{2+}\)-dependent endoribonuclease MRPP3, resulting in the ternary RNase P complex that performs 5′-end pre-(mt)tRNA processing (28). The mature MRPP3 protein (MRPP3\(_{\text{AMTS}}\)) contains an N extension (aa 51–206), a pentatricopeptide repeat (PPR) domain (aa 207–328), the first half of a core domain (aa 329–360), a catalytic NYN domain (aa 360–541), and the second half of the core domain (aa 342–583) (Fig. 5A). The mature MRPP3 protein (MRPP3\(_{\text{AMTS}}\)) contains an N extension (aa 51–206), a pentatricopeptide repeat (PPR) domain (aa 207–328), the first half of a core domain (aa 329–360), a catalytic NYN domain (aa 360–541), and the second half of the core domain (aa 342–583) (Fig. 5A).

MRPP3 is expected to be the catalytic subunit of this RNase P complex, although it is unclear how MRPP3 interacts with the binary complex of MRPP1–MRPP2 or the pre-(mt)tRNA substrate.

We reconstituted the ternary complex (Fig. 5A and Fig. 5C) by mixing MRPP3 (Fig. S4A) with MRPP1 and MRPP2 that were either expressed individually or co-expressed. A preincubated mixture of MRPP1\(_{\text{AMTS}}\), MRPP2, and MRPP3\(_{\text{AMTS}}\) was applied to an SEC column, which eluted predominantly as peaks corresponding to the MRPP1–MRPP2 complex and individual proteins, and not the ternary complex (Fig. 5B, top, green line). However, a mixture of the three proteins incubated with excess pre-(mt)tRNA gave rise to an earlier elution peak than the binary complex, indicating a larger \(M_r\) species (Fig. 5B, top, black line). SDS-PAGE analysis confirmed the presence of all three proteins in this peak (Fig. 5B, bottom). Therefore, the interaction between MRPP3\(_{\text{AMTS}}\) and its two partner proteins, MRPP1\(_{\text{AMTS}}\) and MRPP2, is facilitated by the presence of its pre-tRNA substrate. The C-terminal region of MRPP3 (aa 274–583), harboring the endonuclease domain for the RNase P activity, is not sufficient for complex formation with MRPP1, MRPP2, and pre-(mt)tRNA\(_{\text{Ile}}\) (Fig. S4B).

The in vitro RNase P activity of the reconstituted MRPP1–MRPP2–MRPP3 complex was measured by probing the formation of 5′-end cleavage products of the pre-(mt)tRNA\(_{\text{Ile}}\) substrate. The assay was set up with complex samples reconstituted from mature proteins, and fragments of MRPP1 (Fig. 5C) and MRPP3 (Fig. 5D). Detection of substrate and cleavage products was carried out with a denaturing urea-polyacryl-
amide gel stained for RNA. The presence of processed (mt)tRNA and 5’-leader by-product was observed in the reaction lane containing all three proteins together with the pre-(mt)tRNA substrate (Fig. 5D, lane 3), confirming RNase P activity for the reconstituted ternary complex. Consistent with previous studies (28), MRPP3 protein alone did not show any RNase P activity toward pre-(mt)tRNA alone (lanes 1 and 1*), a mixture of pre-(mt)tRNA and the complex of MRPP1<sub>ΔMTS</sub> and MRPP2 loaded at the same concentration as in lanes 2 and 2* (lanes 4 and 4*) and at half that concentration (lanes 3 and 3*). The gel was stained for RNA (lanes 1*–4* and protein (lanes 1–4), including M<sub>1</sub> protein markers (M). Lanes shown are taken from two gels, with the protein marker lane used for lane alignment. C, native PAGE nondenaturing gels stained similarly as for B, containing samples of pre-(mt)tRNA alone (lanes 1 and 1*), MRPP1<sub>14</sub> and MRPP2<sub>4</sub>, a mixture of pre-(mt)tRNA and MRPP1<sub>3</sub> (lanes 3 and 3*), a mixture of MRPP1<sub>4</sub>, MRPP2<sub>4</sub> and MRPP2 (lanes 4 and 4*), and a mixture of pre-(mt)tRNA, MRPP1<sub>4</sub> and MRPP2 (lanes 5 and 5*). The gel sections were stained for RNA (lanes 1*–5*) and protein (lanes 1–5), including M<sub>1</sub> protein markers (M). Lanes shown are taken from one gel, with the protein marker lane used for lane alignment. D, measurement of m<sub>1</sub>G MTase (substrate: pre-(mt)tRNA<sub>Val</sub>) and m<sub>1</sub>A MTase (substrate: pre-(mt)tRNA<sub>Thr</sub>) activities for MRPP1<sub>ΔMTS</sub> and various individual domains and catalytic mutants (D314N and Q226A) applied with and without MRPP2, shown as a bar chart of the measured radioactivity (cpm) incorporated into tRNA. E, measurement of SDR activity of MRPP2 alone and in complex with MRPP1<sub>ΔMTS</sub> using the substrate allopregnanolone, shown as a plot of the relative fluorescence (relative fluorescence units, mAU) against the concentration of substrate (µM). Kinetic parameters for the <i>K<sub>m</sub></i> and maximal velocity (<i>V</i><sub>max</sub>) were calculated from Michaelis–Menten fitting of the shown curve using GraphPad Prism. mAU, milli-absorbance units.

**Small angle X-ray scattering (SAXS) modeling of individual proteins and complexes**

We utilized SAXS to characterize the solution state of the binary complex (MRPP1<sub>ΔMTS</sub>–MRPP2) as well as the binary and ternary complexes in the presence of pre-(mt)tRNA<sub>Val</sub> (MRPP1<sub>ΔMTS</sub>–MRPP2–tRNA and MRPP1<sub>ΔMTS</sub>–MRPP2–MRPP1<sub>ΔMTS</sub>–tRNA, respectively). To ensure that scattering data were measured on monodisperse samples, SAXS measurements were performed as analytical, size-exclusion chromatographic separations connected in-line to a SAXS flow cell. The scattering data for the various complexes were collected (Fig. S6, C, D, and G) and processed (Fig. S7) to determine the radius of gyration (<i>R</i><sub>g</sub>), particle volume, and maximal intraparticle dimension (<i>D</i><sub>max</sub>) values (Table 2). Shape restoration from the scattering data yielded <i>ab initio</i> molecular envelopes for the three complexes (Fig. 6, D, E, F, and G).

We attempted to model the three component proteins and tRNA substrate into the complex envelopes. To do so, we first derived molecular envelopes for the individual proteins based
Figure 5. Characterization of MRPP3\textsubscript{AMTS}, alone and in complex with MRPP1\textsubscript{AMTS} and MRPP2. A, domain organization for MRPP3\textsubscript{AMTS}, indicating the N-terminus (residues 50–206), PPR domain (residues 207–329; red), core domain (residues 330–361 and 542–583; yellow), NYN domain (residues 362–541; brown), and structural zinc ion bound in a Cys-Cys-His-Cys motif in the core domain. B, top, analytical SEC profiles for the mixture of MRPP1\textsubscript{AMTS}, MRPP2, and MRPP3\textsubscript{AMTS} (green line) and the mixture of MRPP1\textsubscript{AMTS}, MRPP2, MRPP3\textsubscript{AMTS} and pre-(mt)\textsubscript{tRNA}\textsuperscript{ile} (black line) applied to a Superdex S200 column. A replicate of this experiment is shown in Fig. S5. The elution volumes for individual MRPP1\textsubscript{AMTS} (from Fig. 3A), MRPP2 (from Fig. 3A), and MRPP3\textsubscript{AMTS} (from Fig. S4) proteins, as well as the mixture of MRPP1\textsubscript{AMTS} and MRPP2 (from Fig. 3A), are indicated with arrows above the chromatogram (blue, orange, red, and pink, respectively). Bottom, SDS-PAGE (first two gel panels) and urea-PAGE (last two gel panels) analysis of eluted fractions to visualize proteins and pre-(mt)\textsubscript{tRNA}\textsuperscript{ile}, respectively. The black dashed box indicates lanes where the complex containing MRPP1\textsubscript{AMTS} and MRPP2, and pre-(mt)\textsubscript{tRNA}\textsuperscript{ile} would be found on the SDS-PAGE. C, urea-polyacrylamide denaturing gels showing the RNase P reaction of pre-(mt)\textsubscript{tRNA}\textsuperscript{ile} set up for the complex of MRPP1\textsubscript{AMTS} and MRPP2 without MRPP3 (lane 2) and in the presence of different truncated MRPP3 proteins (lanes 3–6). A negative control of MRPP1\textsubscript{AMTS}, MRPP2, and MRPP3\textsubscript{AMTS} mixed with EDTA (lane 1) is included. M, RNA markers are shown (lane M). All lanes shown were run for 30 min at protein concentrations of 300 nm MRPP1–MRPP2 and 150 nm MRPP3.

With the above models in place, we docked the component subunits incrementally into the complex envelopes. The MRPP1\textsubscript{AMTS}–MRPP2 envelope was processed in both P1 and P2 point groups to account for monomeric and dimeric MRPP1\textsubscript{AMTS} Protein, respectively. The molecular mass derived from the scattering curve of 190 kDa is consistent with the SEC-MALS data. The mixture of MRPP1\textsubscript{AMTS}, MRPP2, and MRPP3\textsubscript{AMTS} would be found on the SDS-PAGE. C, urea-polyacrylamide denaturing gels showing the RNase P reaction of pre-(mt)\textsubscript{tRNA}\textsuperscript{ile} set up for the complex of MRPP1\textsubscript{AMTS} and MRPP2 without MRPP3 (lane 2) and in the presence of different truncated MRPP3 proteins (lanes 3–6). A negative control of MRPP1\textsubscript{AMTS}, MRPP2, and MRPP3\textsubscript{AMTS} mixed with EDTA (lane 1) is included. M, RNA markers are shown (lane M). All lanes shown were run for 30 min at protein concentrations of 300 nm MRPP1–MRPP2 and 150 nm MRPP3.

on their own scattering data (Fig. S6, A, B, E, and F). The isolated MRPP1\textsubscript{AMTS} was found to exist as both monomer and dimer in solution. The obtained SAXS envelope could therefore account for a dimer containing two MTase domains at opposite ends sandwiching two compact, interacting N-terminal domains in the center (Fig. 6A) or could alternatively comprise only one MTase domain at one end of the pocket with an elongated, flexible N-terminal domain taking up the remaining space. A similarly elongated SASX envelope was seen for the monomeric Trm10 homologue of MRPP1 from yeast in solution (15). For MRPP2, a calculated scattering curve for the tetrameric crystal structure provides an excellent fit ($\chi^2 = 0.952$ for $q$ values between 0.01 and 0.45°) to the scattering data (Fig. S8B), and the structure can be easily modeled into the low-resolution envelope (Fig. 6B). The modeled envelope for MRPP3\textsubscript{AMTS} accommodates the reported crystal structure (aa 207–583, MRPP3\textsubscript{206}) while leaving room only for the N-terminal extension (aa 51–206) not present in the structure (Fig. 6C). As a control, we measured scattering data for MRPP3\textsubscript{206} protein, which shows a good fit ($\chi^2 = 1.74$ for $q$ values between 0.01 and 0.45°) to the structure (Fig. S8C). Both MRPP3\textsubscript{AMTS} and MRPP3\textsubscript{206} envelopes indicate a monomeric protein that is supported by analytical SEC (Fig. S4F) and in line with MRPP3 orthologues from A. thaliana (PRORP1 and PRORP2) (42).

With the above models in place, we docked the component subunits incrementally into the complex envelopes. The MRPP1\textsubscript{AMTS}–MRPP2 envelope was processed in both P1 and P2 point groups to account for monomeric and dimeric MRPP1\textsubscript{AMTS} Protein, respectively. The molecular mass derived from the scattering curve of 190 kDa is consistent with the SEC-MALS data, agreeing with a 2 MRPP1 to 4 MRPP2 stoichiometry. The envelope obtained from processing in P2 contains a globular region in the center, where one MRPP2 tetramer can be fitted, and two smaller peripheral regions sandwiching MRPP2, where each region could accommodate one MRPP1 monomer (Fig. 6E). The envelope from processing in P1 shows a similar globular region corresponding to the MRPP2 tetramer, but also an extended region representing an MRPP1 domain organization for MRPP3 (from Fig. 3), MRPP2 (from Fig. 3A), and MRPP3\textsubscript{AMTS} (from Fig. S4) proteins, as well as the mixture of MRPP1\textsubscript{AMTS} and MRPP2 (from Fig. 3A), are indicated with arrows above the chromatogram (blue, orange, red, and pink, respectively). Bottom, SDS-PAGE (first two gel panels) and urea-PAGE (last two gel panels) analysis of eluted fractions to visualize proteins and pre-(mt)\textsubscript{tRNA}\textsuperscript{ile}, respectively. The black dashed box indicates lanes where the complex containing MRPP1\textsubscript{AMTS} and MRPP2, and pre-(mt)\textsubscript{tRNA}\textsuperscript{ile} would be found on the SDS-PAGE. C, urea-polyacrylamide denaturing gels showing the RNase P reaction of pre-(mt)\textsubscript{tRNA}\textsuperscript{ile} set up for the complex of MRPP1\textsubscript{AMTS} and MRPP2 without MRPP3 (lane 2) and in the presence of different truncated MRPP3 proteins (lanes 3–6). A negative control of MRPP1\textsubscript{AMTS}, MRPP2, and MRPP3\textsubscript{AMTS} mixed with EDTA (lane 1) is included. M, RNA markers are shown (lane M). All lanes shown were run for 30 min at protein concentrations of 300 nm MRPP1–MRPP2 and 150 nm MRPP3.

With the above models in place, we docked the component subunits incrementally into the complex envelopes. The MRPP1\textsubscript{AMTS}–MRPP2 envelope was processed in both P1 and P2 point groups to account for monomeric and dimeric MRPP1\textsubscript{AMTS} Protein, respectively. The molecular mass derived from the scattering curve of 190 kDa is consistent with the SEC-MALS data, agreeing with a 2 MRPP1 to 4 MRPP2 stoichiometry. The envelope obtained from processing in P2 contains a globular region in the center, where one MRPP2 tetramer can be fitted, and two smaller peripheral regions sandwiching MRPP2, where each region could accommodate one MRPP1 monomer (Fig. 6E). The envelope from processing in P1 shows a similar globular region corresponding to the MRPP2 tetramer, but also an extended region representing an MRPP1 dimer (Fig. 6D). When comparing the Kratky plots for isolated MRPP1\textsubscript{AMTS} and MRPP1\textsubscript{AMTS} complexed with MRPP2, it can be easily seen that any flexibility found in isolated MRPP1\textsubscript{AMTS} is lost when bound to MRPP2, giving rise to a more compact structure (Fig. S8D).
Study of a methyltransferase and RNase P

Table 2

Parameters derived from small angle x-ray scattering studies of MRPP1$_{\text{MTS}}$, MRPP2, MRPP3$_{\text{MTS}}$, and their complexes

*Ab initio* model-building statistics are given. Guinier $R_g < 1.3$ for all data sets. (0), forward scattering; $R_g$, radius of gyration; a.u., arbitrary units; $RS-R_g$, real-space radius of gyration; Porod $V$, Porod volume; $D_{\text{max}}$, maximal intraparticle dimension. a.u., absorbance unit.

|                | MRPP1 | MRPP2 | MRPP3 | Δ206-MRPP3 | MRPP1-MRPP2 | MRPP1-MRPP2-pre-tRNA$^{16}$ | MRPP1-MRPP2-MRPP3-pre-tRNA$^{16}$ |
|----------------|-------|-------|-------|------------|-------------|-----------------------------|----------------------------------|
| Guinier $R_g$ (Å) | 40.10 ± 2.89 | 29.24 ± 0.95 | 33.79 ± 1.15 | 33.30 ± 1.52 | 46.77 ± 1.16 | 72.71 ± 5.45 | 108.8 ± 7.25 |
| $I(0)$ (×10$^{-1}$ a.u.) | 3.02 ± 0.29 | 9.07 ± 0.25 | 9.23 ± 4.68 | 2.87 ± 0.46 | 23.42 ± 0.71 | 21.71 ± 1.53 | 42.87 ± 4.01 |
| $RS-R_g$ (Å) | 34.40 ± 1.88 | 92.44 ± 0.44 | 33.18 ± 1.21 | 28.83 ± 1.47 | 45.59 ± 0.97 | 69.67 ± 2.77 | 82.60 ± 0.95 |
| Porod $V$ (Å$^3$) | 174,930 | 167,454 | 306,000 | 167,576 | 873,102 | 1,279,622 | 4,077,408 |
| $E_{\text{max}}$ (Å) | 100 | 80 | 111 | 98 | 154 | 216 | 248 |

Model building

| Point symmetry | P1 | P1 | P1 | P1 | P1 | P1 |
|----------------|----|----|----|----|----|----|
| Models generated | 13 | 13 | 13 | 13 | 13 | 13 |
| Models included* | 12 | 13 | 13 | 12 | 13 | 12 |
| $\chi^2$ versus raw data | 2.72 | 1.04 | 2.08 | 1.71 | 1.37 | 1.50 |

* Models discarded when NSD > NSD$_{\text{mean}}$ + 2×S.D., n = 12–13.

Figure 6. Low-resolution models from small angle X-ray scattering. Shown are *ab initio* envelopes derived from scattering data for MRPP1$_{\text{MTS}}$ (A), MRPP2 (B), MRPP3$_{\text{MTS}}$ (C), complex containing MRPP1$_{\text{MTS}}$ and MRPP2 processed in point group P1 (D), complex containing MRPP1$_{\text{MTS}}$ and MRPP2 processed in point group P2 (E), MRPP1$_{\text{MTS}}$–MRPP2–(pre)tRNA$^{16}$ processed in point group P1 (F), MRPP1$_{\text{MTS}}$–MRPP2–(pre)tRNA$^{16}$–MRPP3$_{\text{MTS}}$ Processed in point group P1 (G). In A, the three views are related by 90° rotations along the x axis and y axis. For B–D, the two views are related by 90° rotations along the x axis, and for E–G, the two views are related by 90° along the y axis. Crystal structures, wherever available, are fitted into the envelopes for MRPP2 (orange; PDB entry 1U7T) and MRPP3$_{\text{MTS}}$ (red; PDB entry 4XGL), and MRPP1$_{\text{MTS}}$ (blue; this study) in the situation where this exists as a dimer. In empty spaces of the envelopes where no crystal structures were fitted, the putative locations for certain subunits or domains are proposed. * views where MRPP2 (orange) is shown in the same orientation.

MRPP2–tRNA complex, compared with the MRPP1–MRPP2 complex. The pre-(mt)tRNA$^{16}$ cannot be modeled accurately due to the large 5’- and 3’-overhangs, but the presumed position can be in close proximity to the m$^{120}$ MTase active site and an N domain, consistent with our finding that the N domain of MRPP1 alone can bind tRNA.

The MRPP1$_{\text{MTS}}$–MRPP2–MRPP3$_{\text{MTS}}$–tRNA complex was prepared by reconstituting MRPP1$_{\text{MTS}}$–MRPP2 with pre-(mt)tRNA$^{16}$ in the presence of Mg$^{2+}$ and a catalytic mutant MRPP3(D479A) (43, 44) (Fig. S4D) used to prevent turnover of the pre-(mt)tRNA$^{16}$, which may dissociate the complex. The *ab initio* model generated from the scattering data with no enforced symmetry reveals a lobe adjacent to the putative MRPP2 and tRNA regions, which can accommodate one MRPP3$_{\text{MTS}}$ molecule (Fig. 6G). Thus, our model proposes a stoichiometry of 2 MRPP1$_{\text{MTS}}$, 4 MRPP2, 1 MRPP3$_{\text{MTS}}$, and 1 pre-(mt)tRNA$^{16}$ molecule. This model would suggest a direct interaction between MRPP2 and MRPP3$_{\text{MTS}}$, possibly without MRPP1$_{\text{MTS}}$ involvement. Nevertheless, size-exclusion chromatography of a mixture containing MRPP2 and MRPP3$_{\text{MTS}}$ (in the absence of pre-(mt)tRNA$^{16}$ substrate) did not reveal the presence of a stable subcomplex (Fig. S4E).
In this study, we characterized biochemically and structurally the MRPP1 protein and its interaction with MRPP2, MRPP3, and tRNA. This work reveals the first structural models for the unique binary and ternary complexes that are responsible for mitochondrial tRNA processing.

The eukaryote-only MRPP1 appears to exist as both monomer and dimer in solution, with dimerization taking place via the N domain. The prompting of dimerization by the N-terminal domain contrasts with canonical SPOUT from other sub-families (e.g. TrmL and TrmH), where homodimerization takes place via their MT domains. Our structure explained why the conventional SPOUT dimer interface is absent in MRPP1. The dimerization of eukaryote-only MRPP1 also contrasts with other characterized Trm10 members from Archaea and lower eukaryotes that clearly exist as monomers in their full-length proteins (15, 35). Like MRPP1, the MT-domain topology of these members also prohibits SPOUT-like dimerization. The known Trm10 family members also contain N and C extensions of different lengths, in addition to their MT domain, displaying low sequence identity, which might explain the unique self-interaction found for this domain in MRPP1.

To date, the Trm10 family members have been characterized to be m1G9-specific (S. cerevisiae and S. pombe), m1A9-specific (S. acidocaldarius), and m1A9/m1G9 dual-specific (MRPP1 and T. kodakaraensis) MTases. The MRPP1–MRPP2 complex harboring either D314N or Q226A substitution on MRPP1 demonstrated no m1A9 and m1G9 MTase activity, thus confirming essential catalytic roles for these strictly invariant residues. During methyl transfer, Asp-314 can activate the N1 atom of G9 and exocyclic N6 atom of A9 to launch a nucleophilic attack on the reactive methyl group of SAM. The catalytic role of Gln-226 is less clear. Ala substitution of the equivalent Gln residue in yeast Trm10 showed that pre-(mt)tRNA or SAM binding was unaffected (15). Instead, Gln-226 could be involved in binding the phosphate group in purine-9 of the (mt)tRNA, as suggested for a corresponding Asn residue in TrmL and TrmH from bacteria (45, 46). The molecular basis of purine specificity in the Trm10 family will be clarified by substrate-bound crystal structures in the future.

The fact that MRPP1 requires an additional partner protein for catalysis contrasts with all functionally characterized Trm10. For example, human cytosolic TRMT10A alone can catalyze m1G9 formation in vitro (16). The functional discrepancy is probably due to differentiating features in the N- and C-terminal extensions of the MT domains, as this domain is highly superimposable among Trm10s. Our SPOT analysis identifies regions from both the N and MT domains of MRPP1 to be involved in MRPP2 interaction. These sequentially disjointed regions can spatially orient into one pan-interaction patch or interact with MRPP2 as separate modules. Two missense mutations in MRPP1 (R118L and T272A), reported to cause a rare systemic mitochondrial disease (19–21), are located within this putative interaction patch, suggesting that these mutations could affect complex formation. We detected a direct interaction between the N domain of MRPP1 and tRNA, and a lack of this domain also abolished dimerization and MTase activity.

In addition to assistance in catalysis, the interaction with MRPP2 also affects the structural integrity of MRPP1, as suggested before (40). Our co-expression experiment suggests that the stability of MRPP1, particularly its N domain, toward proteolytic degradation depends on the presence of MRPP2. A comparison of SAXS data (Kratky plot) between MRPP1 alone and MRPP1 complexed with MRPP2 showed that MRPP1 becomes structurally more compact when bound to MRPP2, whereas MRPP1 is prone to degradation in the absence of MRPP2. We therefore speculate that the dimer formation of MRPP1 alone via the N domain is an in vitro observation induced by the absence of MRPP2. Such self-interaction of MRPP1 in a dimer would stabilize an otherwise monomeric MRPP1 protein, preventing its degradation at the N domain. We would further envisage that in the cell, MRPP1 would largely be present in complex with MRPP2.

Our combinatorial solution studies (SAXS and SEC-MALS) revealed a 2:4 stoichiometry for the MRPP1–MRPP2 complex, as suggested previously (28, 47). We envisage two possible subunit arrangements, backed by SAXS data processing, that could account for such stoichiometry. On the one hand, the SAXS envelope processed with P2 symmetry favored the fitting of two MRPP1 monomers on distal sides of the MRPP2 tetramer in a symmetrical manner. On the other hand, the SAXS envelope without enforced symmetry would suggest binding of an MRPP1 homodimer to only one face of the MRPP2 homotetramer, implying that MRPP1 would contact MRPP2 in an asymmetric manner, a scenario that is difficult to reconcile, considering the symmetrical shape of MRPP2 homotetramer. Future high-resolution structural studies to resolve the two possibilities are clearly warranted.

SAXS studies on MRPP1–MRPP2–tRNA complex, processed without forced symmetry, suggested one pre-(mt)tRNA molecule bound per MRPP1–MRPP2 complex and that tRNA binding could rearrange the relative orientation between MRPP1 and MRPP2. The stoichiometry of one tRNA substrate per MTase dimer has been shown for TrmH and TrmD (45, 48, 49). EMSA showed that MRPP1, similarly to TrmD and TrmH, involves regions beyond the MT domain for binding pre-(mt)tRNA, although the N-terminal non-MT regions in TrmD and TrmH are significantly shorter than the MRPP1 N domain. The assistance in tRNA binding by regions beyond the MT domain is shown for many SPOUT members (15, 35, 48, 50). It is possible that these non-MT domains are tasked to recognize more universally conserved parts of the tRNAs if the immediate environment around the modified nucleotide, in contact with the MT domain, shows low structural conservation.

A direct interaction between MRPP2 and the (mt)tRNA substrate has previously been suggested, based on the discovery that NAD+/NADH-binding Rossmann folds could accommodate RNA (51, 52) and on in vitro interaction data (53). We, in addition to Vilardo et al. (16), however, did not detect any direct interaction in vitro between recombinant MRPP2 and pre-(mt)tRNA using EMSA. It is currently unclear how the MRPP1–MRPP2 interaction would influence the binding of the (mt)tRNA substrate. A small increase in the dissociation con...
catalytically important structural element in MRPP1 (assisting in direct interaction with (mt)tRNA, 2) stabilizing an activity toward the tested pre-(mt)tRNAIle substrate. No RNase ternary complex, but not MRPP3 alone, exhibited RNase P presence of the pre-(mt)tRNA substrate. This reconstituted domain. Future studies are required to further explore these possible mechanisms.

The MRPP1–MRPP2–MRPP3 complex is formed only in the presence of the pre-(mt)tRNA substrate. This reconstituted ternary complex, but not MRPP3 alone, exhibited RNase P activity toward the tested pre-(mt)tRNAIle substrate. No RNase P activity was observed for the ternary complex in the absence of either the PPR-domain or the core/NYN domains of MRPP3, but partial removal of the N extension (43 residues) still left a functional protein. Again, it is intriguing that the RNase P activity of MRPP3 depends so strongly on additional protein partners, when MRPP3 homologues from lower eukaryotes efficiently perform the 5′-end processing on their own (54, 55). The SAXS model obtained without enforced symmetry supported a stoichiometry of MRPP1 (dimer):MRPP2 (tetramer): MRPP3 (monomer):pre-(mt)tRNA (one molecule). MRPP3 alone is a monomer in solution and in the crystal, and it is therefore not surprising that it could exist as such in the complex.

(mt)tRNAs often adopt “bizarre” structures, especially before they undergo posttranscriptional modifications. It is possible that the MRPP1–MRPP2 complex activates the pre-(mt)tRNA for recognition by MRPP3, by remodeling the (mt)tRNA in a way that offers a similar recognition surface for MRPP3 across all bizarre (mt)tRNAs. The role of MRPP1–MRPP2 as the pre-(mt)tRNA recognition component of the RNase P complex is in line with findings herein that the MRPP1–MRPP2 complex can bind the pre-(mt)tRNA before binding of MRPP3. Structural studies of MRPP3 alone have revealed the absence of Mg2+ cofactor in the active site (43, 44). Binding of MRPP1–MRPP2 and/or tRNA could therefore configure MRPP3 into a conformation that allows binding of the Mg2+ cofactor necessary for pre-(mt)tRNA 5′-end processing.

Experimental procedures

Cloning, expression, and purification of MRPP1, MRPP2, and MRPP3

DNA fragments representing the human MRPP1, MRPP2, or MRPP3 (MGC collection 4719195, 2819721, or 5206545) were subcloned into pNIC28-Bsa4 vector (GenBank™ EF198106) incorporating an N-terminal His6 tag. Constructs were generated of MRPP1 covering residues 40–403 (MRPP1N), 195–403 (MRPP1MT), 203–403 (MRPP1MT+C195), and of MRPP2 covering residues 51–583 (MRPP2N), 95–583 (MRPP2NTS), 96–274 (MRPP3N), and 274–583 (MRPP3C). To generate an MRPP1–MRPP2 coexpression plasmid, a DNA fragment of human MRPP1 and MRPP2, interspersed with a ribosome-binding site, was subcloned into the pNIC28-Bsa4 vector. MRPP1 and MRPP3 mutations were generated using the QuikChange site-directed mutagenesis kit (Agilent), based on the pNIC28-Bsa4 vector containing full-length His6-MRPP3 alone (for MRPP3) or both mature His6-MRPP1 and full-length MRPP2 in a bicistronic transcript (for MRPP1). The presence of the DNA changes was verified by Sanger sequencing.

Plasmids were transformed into E. coli BL21(DE3)-R3-pRARE2 competent cells, cultured in Terrific Broth at 37 °C, and protein expression was induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside for overnight growth at 18 °C. For small-scale expression and solubility test, cell pellets from 50-ml cultures were lysed by sonication and clarified by centrifugation, and the clarified lysate was applied to an immobilized metal affinity column (IMAC) for protein purification.

For large-scale purification for biochemical assays, MRPP2 (WT and mutants), co-expressed MRPP1–MRPP2 complex, and MRPP3 cell pellets from 3–12-liter cultures were lysed as described above, and recombinant proteins were purified by IMAC and size-exclusion chromatography, treated with tobacco etch virus protease overnight, and further purified by reverse IMAC and ion-exchange chromatography eluted with a NaCl gradient (supporting Experimental procedures for protein purification).

In vitro transcription of mitochondrial tRNA precursors

cDNAs representing human mitochondrial tRNA<sup>he</sup> and tRNA<sup>Val</sup> precursors were designed with leader and trailer sequences of 30 and 15 nucleotides, respectively, and in vitro transcribed from a PCR-amplified template by T7 RNA polymerase using the Transcript Aid T7 high-yield transcription kit (Thermo Scientific). The transcribed precursor tRNAs were purified using the RNeasy Mini Kit (Qiagen).

Crystallization, data collection, and structure determination

Crystals of hMRPP1<sub>WT+Cl(2A02)</sub> were grown by vapor diffusion at 4 °C, from sitting drops composed of 200 nl of protein (11 mg/ml; preincubated with 4.8 μM SAM) and 100 nl of reservoir solution containing either 14% PEG 1000, 28% glycerol or 12% PEG 1000, 28% glycerol, 1.5% (w/v) PEG 3350. Crystals were cryo-protected with reservoir solution supplemented with 25% (v/v) propylene glycol and flash-cooled in liquid nitrogen. Heavy atom (HA)-(DA)-derivatized crystals were obtained by soaking with 10 mM Ca<sub>2+</sub> to 2.49 Å and for two crystals of the as-purified protein to 2.22 and 1.96 Å. Phases were determined by SIRAS with the SHELX package (56) using the HA data set. This model was used as search model in a molecular replacement procedure in Phaser (58) in the CCP4 suite of programs (59) using the native data collected to 1.96 Å. Modeling and refinement were carried out using Refmac (60) and Coot (61). There was no electron density for residues 380–403 and lower than average electron density for residues 343–348 in all chains.
Analytical SEC

100-μl protein samples of varying concentrations were injected onto a 24-ml Superdex S200 10/300 GL column (GE Healthcare) or a KW403-4F column (Shodex). Fractions were collected, and TCA was precipitated before analysis on a 4–12% bis-tris polyacrylamide gel (Invitrogen). Molecular weight standards from Bio-Rad, containing thyroglobulin (670 kDa), γ-globulin (158 kDa), ovalbumin (44 kDa), and myoglobin (17 kDa), and vitamin B₁₂ (13.5 kDa) were used for calibration (Fig. S1A). Complex formation and molecular weights were determined from experimental replicates of n = 3.

DSF

DSF was performed in a 96-well plate using an Mx3005p RT-PCR machine (Stratagene) with excitation and emission filters of 492 and 610 nm, respectively. Each well consisted of 2 μl of protein in a buffer of 150 mM NaCl, 10 mM HEPES, pH 7.5, to a final concentration of 2 μM, 2 μl SYPRO ORANGE diluted 1000-fold in buffer from the manufacturer’s stock (Invitrogen), and (if applicable) 2 μl of ligand at various concentrations. Fluorescence intensities were measured from 25 to 96 °C with a ramp rate of 3 °C/min. T_m was determined by curve fitting using GraphPad Prism version 5.01 software (62). Data were evaluated using a standard P-test according to a standard procedure performed using the GraphPad Prism version 5.01 software.

SPOT blot assay

15-Mer peptides of mature MRPP1 (residues 40–403), with maximum overlap of 13 amino acids from the peptide before or after (i.e. a two-amino acid shift in register), were synthesized on cellulose membranes using a MultiPep SPOT peptide arrayer (Intavis). In the synthesis, some spots were left blank (no peptide coupled), and some were coupled only to His₆ to serve as controls. His₆-tagged MRPP2 was added to a final concentration of 1 μM and detected with horseradish peroxidase–conjugated anti-His antibody in a 1:3000 dilution in 2.5% BSA PBST buffer. Blots were developed using an ECL kit (Thermo Scientific) with equal amounts of peroxide solution and luminol enhancer solution. Membrane spots were visualized with an ImageQuant Las-4000 camera (Fujifilm) on the chemiluminescence setting. Densitometry was performed using E-editor version 2.0 software.

tRNA binding by EMSA

EMSA was performed in a 12-μl reaction mixture: 100 mM NaCl, 50 mM Tris-HCl, pH 8.0, 3 mM DTT, 3 mM MgCl₂, 1 μM tRNA, and the proteins at 9–16 μM. Reaction mixtures were incubated on ice for 10 min, mixed with 6 μl of EMSA loading buffer, and applied to a nondenaturing 3–8% Tris acetate polyacrylamide gel (NuPAGE, Invitrogen) along with a sample of protein markers (NativeMark™ unstained protein ladder, Thermo Fisher Scientific) and electrophoresed in Tris/glycine buffer at 4 °C for 2 h, 40 min at a constant voltage of 150 V. Subsequently, gel was stained with SYBR Gold (1:1000 dilution in Tris/glycine buffer) for 30 min and imaged using the Bio-Rad ChemiDoc imaging system. Coomassie Brilliant Blue (Gen-
Study of a methyltransferase and RNase P

models were built using DAMMIF in fast computation mode with all three point groups. The NSD values were calculated for each generated model using SUPCOMB and subsequently compared to find the most probable ones using DAMSEL, with exclusion of models with NSD > mean + 2 × S.D. The most probable models were aligned using DAMSUP, averaged using DAMAVER, and filtered according to volume by DAMFILT (63). From the filtered model, a core structure was generated in DAMSTART from which a refined model was built in slow computational mode using DAMMIN, with P1, P2, or P4 point symmetry (64). The scattering data for the MRPP1–MRPP2 complex processed in all three point groups (Table S1 and Fig. S8A) were compared with ab initio models for the separate protein components to identify the correct model as P1 or P2 (Fig. 6, D and E). Protein complexes including pre- (mt) tRNA were subsequently processed in P1 only, as no specific symmetry could be assumed in such a multispecies arrangement (Fig. 6, F and G). Protein M values were determined using the shape- and fold-independent volume of correlation (Vc)–based approach in Scatter (version 3.0) (65) (MRPP1−1MTS−MRPP2) or determined directly from the scattering curve using SAXS MoW2, with the assumption that the proteins adopt a globular structure (MRPP2) (66).

**SEC–MALS**

MALS studies were performed in-line with SEC on protein samples to assess monodispersity and mass of the SAXS samples using an 18-angle DAWN HELEOS light-scattering (LS) detector in which detector 12 was replaced with a DynaPro quasi-elastic light-scattering detector (Wyatt Technology). Simultaneous concentration measurements were made with an Optilab REX refractive index detector (Wyatt Technology) connected in tandem to the LS detector. The MALS system was calibrated with BSA and glucose isomerose at 10 mg/ml to determine delay times, band broadening, and refractive index increment. Chromatographic separation was performed with a KW403–4F column (Shodex) at 4.5 mg/ml in 50 mM sodium phosphate, pH 7.4, 300 mM NaCl, 5% glycerol, 1% sucrose, 0.5 mM TCEP (for MRPP1, MRPP2, and MRPP1–MRPP2) using a flow rate of 0.250 ml/min.

**Author contributions**—U. O. and W. W. Y. conceived the project. S. O. carried out the protein purification, crystallization, structure determination, and biochemical experiments. M. R. and L. D. contributed to the methyltransferase assay. F. F. contributed to protein purification and crystallization. J. K. and J. A. N. contributed to structure determination. S. O., R. P. R., H. J. B., W. G. N., A. A., J. Z., U. O., W. W. Y. analyzed data and contributed to the writing of the manuscript. All authors reviewed and approved the manuscript.

**Acknowledgments**—We thank Panagis Filippakopoulos and Sarah Picaud for peptide synthesis and membrane coupling for the SPOT blot analysis. We thank Rod Chalk and Octawia Borkowska for MS analysis.

**References**

1. Anderson, S., Bankier, A. T., Barrett, B. G., de Bruijn, M. H., Coulson, A. R., Drouin, J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., Schreier, P. H., Smith, A. J., Staden, R., and Young, I. G. (1981) Sequence and organization of the human mitochondrial genome. *Nature* **290**, 457–465 CrossRef Medline

2. Phizicky, E. M., and Hopper, A. K. (2010) tRNA biology charges to the front. *Genes Dev.* **24**, 1832–1860 CrossRef Medline

3. Motorin, Y., and Helm, M. (2011) RNA nucleotide methylation. *Wiley Interdiscip. Rev. RNA* **2**, 611–631 CrossRef Medline

4. Motorin, Y., and Helm, M. (2010) tRNA stabilization by modified nucleotides. *Biochemistry* **49**, 4934–4944 CrossRef Medline

5. Cantara, W. A., Crain, P. F., Rozenski, J., McCloskey, J. A., Harris, K. A., Zhang, X., Vendeix, F. A. P., Fabris, D., and Agris, P. F. (2011) The RNA modification database, RNAMDB: 2011 update. *Nucleic Acids Res.* **39**, D195–D201 CrossRef Medline

6. Czerwoniec, A., Dunin-Horkawicz, S., Purta, E., Kaminksi, K. H., Kasprzak, J. M., Bujnicki, J. M., Grosjean, H., and Rother, K. (2009) MODOMICS: a database of RNA modification pathways: 2008 update. *Nucleic Acids Res.* **37**, D118–D121 CrossRef Medline

7. Suzuki, T., Nagao, A., and Suzuki, T. (2011) Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases. *Annu. Rev. Genet.* **45**, 299–329 CrossRef Medline

8. Jühling, F., Mörl, M., Hartmann, R. K., Sprinzl, M., Stadler, P. F., and Pütz, J. (2009) tRNAdb 2009: compilation of tRNA sequences and tRNA genes. *Nucleic Acids Res.* **37**, D159–D162 CrossRef Medline

9. Helm, M., Brulé, H., Degoul, F., Cepanec, C., Leroux, J.-P., Giegé, R., and Florentz, C. (1998) The presence of modified nucleotides is required for cloverleaf folding of a human mitochondrial tRNA. *Nucleic Acids Res.* **26**, 1636–1643 CrossRef Medline

10. Voigts-Hoffmann, F., Hengscheid, M., Kobiatski, A. Y., van Aerschot, A., Herdewijn, P., Nienhaus, G. U., and Helm, M. (2007) A methyl group controls conformational equilibrium in human mitochondrial tRNAlys. *J. Am. Chem. Soc.* **129**, 13382–13383 CrossRef Medline

11. Suzuki, T., and Suzuki, T. (2014) A complete landscape of post-transcriptional modifications in mammalian mitochondrial tRNAs. *Nucleic Acids Res.* **42**, 7346–7357 CrossRef Medline

12. Anantharaman, V., Koonin, E. V., and Aravind, L. (2002) SPOUT: a class of methyltransferases that includes spuO and tRNA methylase superfamilies, and novel superfamilies of predicted prokaryotic RNA methylases. *J. Mol. Microbiol. Biotechnol.* **4**, 71–75 Medline

13. Tkaczuk, K. L., Dunin-Horkawicz, S., Purta, E., and Bujnicki, J. M. (2007) Structural and evolutionary bioinformatics of the SPOUT superfamily of methyltransferases. *BMC Bioinformatics* **8**, 73 CrossRef Medline

14. Jackman, J. E., Montange, R. K., Malik, H. S., and Phizicky, E. M. (2003) Identification of the yeast gene encoding the tRNA m1G methyltransferase responsible for modification at position 9. *RNA* **9**, 574–585 CrossRef Medline

15. Shao, Z., Yan, W., Peng, J., Zuo, X., Zou, Y., Li, F., Gong, D., Ma, R., Wu, J., Shi, Y., Zhang, Z., Teng, M., Li, X., and Gong, Q. (2014) Crystal structure of tRNA m1G9 methyltransferase Tm10: insight into the catalytic mechanism and recognition of tRNA substrate. *Nucleic Acids Res.* **42**, 509–525 CrossRef Medline

16. Vilardo, E., Nachbagauer, C., Buzet, A., Taschner, A., Holzmann, J., and Rossmanith, W. (2012) A subcomplex of human mitochondrial RNase P is a bifunctional methyltransferase: extensive moonlighting in mitochondrial RNA biogenesis. *Nucleic Acids Res.* **40**, 11583–11593 CrossRef Medline

17. Kempeaers, M., Roovers, M., Oudjama, Y., Tkaczuk, K. L., Bujnicki, J. M., and Droogmans, L. (2010) New archaeal methyltransferases forming 1-methyladenosine or 1-methyladenosine and 1-methylguanosine at position 9 of tRNA. *Nucleic Acids Res.* **38**, 6533–6543 CrossRef Medline

18. Sanchez, M. I., Mercer, T. R., Davies, S. M., Shearwood, A.-M. J., Nygård, K. K., Richman, T. R., Mattick, J. S., Rackham, O., and Filipovska, A. (2011) RNA processing in human mitochondria. *Cell Cycle* **10**, 2904–2916 CrossRef Medline

19. Gillis, D., Krishnamohan, A., Yaacov, B., Shaag, A., Jackman, J. E., and Elpeleg, O. (2014) TRMT10A dysfunction is associated with abnormalities in glucose homeostasis, short stature and microcephaly. *J. Med. Genet.* **51**, 581–586 CrossRef Medline
Study of a methyltransferase and RNase P

structurally diverse substrates by type II 3-hydroxacycl-CoA dehydrogenase (HADH II)/amylloid-β binding alcohol dehydrogenase (ABAD). J. Mol. Biol. 303, 311–327 CrossRef Medline

35. Van Laer, B., Roovers, M., Wauters, L., Kasprzak, J. M., Dyzma, M., Dey- aer, E., Kumar Singh, R., Feller, A., Bujnicki, J. M., Droogmans, L., and Versées, W. (2016) Structural and functional insights into RNA binding and adenosine N1-methylation by an archaeal Trm10 homologue. Nucleic Acids Res. 44, 940–953 CrossRef Medline

36. Krissinel, E. and Henrick, K. (2007) Interference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 CrossRef Medline

37. Elkins, P. A., Watts, J. M., Zalcain, M., van Thiél, A., Vitazka, P. R., Redlak, M., Andraos-Selim, C., Rastinejad, F., and Holmes, W. M. (2003) Insights into catalysis by a knotted TrmD tRNA mMethyltransferase. J. Mol. Biol. 333, 931–949 CrossRef Medline

38. Barraud, P., Golinelli-Pimpanée, B., Atmane, C., Sanglier, S., Van Dorsselaer, A., Droogmans, L., Dardel, F., and Tisné, C. (2008) Crystal structure of Thermus thermophilus tRNA m1A58 methyltransferase and biophysical characterization of its interaction with tRNA. J. Mol. Biol. 377, 535–550 CrossRef Medline

39. Oerum, S., Dégut, C., Barraud, P., and Tisné, C. (2017) m1A post-transcriptional modification in tRNAs. Biomolecules 7, E20 Medline

40. Deutschmann, A. J., Amberger, A., Zavadil, C., Steinbeisser, H., Mayr, I. A., Feichtinger, R. G., Oerum, S., Yue, W. W., and Zschocke, J. (2014) Mutation or knock-down of 17β-hydroxysteroid dehydrogenase type 10 cause loss of MRPP1 and impaired processing of mitochondrial heavy strand transcripts. Hum. Mol. Genet. 23, 3618–3628 CrossRef Medline

41. Frank, R. and Overwin, H. (1996) SPOT synthesis: epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Methods Mol. Biol. 66, 149–169 Medline

42. Gobert, A., Pinker, F., Fuchsberger, O., Gutmann, B., Boutin, R., Roblin, P., Sauter, C., and Giegé, P. (2013) Structural insights into protein-only RNase P complexed with tRNA. Nat. Commun. 4, 1353 CrossRef Medline

43. Reinhard, L., Sridhara, S., and Hällberg, B. M. (2015) Structure of the nucleosome subunit of human mitochondrial RNase P. Nucleic Acids Res. 43, 5664–5672 CrossRef Medline

44. Li, F., Liu, X., Zhou, W., Yang, X., and Shen, Y. (2015) Auto-inhibitory mechanism of the human mitochondrial RNase P protein complex. Sci. Rep. 5, 9878 CrossRef Medline

45. Watanebe, K., Nureki, O., Fukai, S., Ishii, R., Okamoto, H., Yokoyama, S., Endo, Y., and Horii, H. (2005) Roles of conserved amino acid sequence motifs in the SpoU (TrmH) RNA methyltransferase family. J. Biol. Chem. 280, 10368–10377 CrossRef Medline

46. Liu, R. J., Zhou, M., Fang, Z. P., Wang, M., Zhou, X. L., and Wang, E. D. (2013) The RNA recognition mechanism of the minimalist SPOUT methyltransferase, TrmL. Nucleic Acids Res. 41, 7828–7842 CrossRef Medline

47. Vilardo, E. and Rossmanith, W. (2015) Molecular insights into HSD10 disease: impact of SDR5C1 mutations on the human mitochondrial RNase P complex. Nucleic Acids Res. 43, 5112–5119 CrossRef Medline

48. Ito, T., Masuda, I., Yoshida, K., Goto-ito, S., Sekine, S., Suh, S. W., Hou, Y.-M., and Yokoyama, S. (2015) Structural basis for methyl-donor–dependent and sequence-specific binding to tRNA substrates by knotted methyltransferase TrmD. Proc. Natl. Acad. Sci. U.S.A. 112, E4197–E4205 CrossRef Medline

49. Christian, T., Lahoud, G., Liu, C., and Hou, Y. M. (2010) Control of catalytic cycle by a pair of analogous RNA modification enzymes. J. Mol. Biol. 400, 204–217 CrossRef Medline

50. Lv, F., Zhang, T., Zhou, Z., Gao, S., Wong, C. C. L., Zhou, J.-Q., and Ding, J. (2015) Structural basis for SfM1 functioning as a protein arginine methyltransferase. Cell Discov. 1, lump37 CrossRef Medline

51. Pathak, A., Popescu, A., Frazão, C., Arriano, C. M., and Fallo, A. M. (2013) Rossman-fold motifs can confer multiple functions to metabolic enzymes: RNA binding and ribonuclease activity of a UDP-glucose dehydrogenase. Biochem. Biophys. Res. Commun. 430, 218–224 CrossRef Medline
52. Fernández, M. R., Porté, S., Crosas, E., Barberà, N., Farrés, J., Biosca, J. A., and Parés, X. (2007) Human and yeast crystallins bind AU-rich elements in RNA. *Cell. Mol. Life Sci.* **64**, 1419–1427 CrossRef Medline

53. Beckmann, B. M., Horos, R., Fischer, B., Castello, A., Eichelbaum, K., Alleaume, A.-M., Schwarzl, T., Curk, T., Foehr, S., Huber, W., Krijgsvedl, J., and Hentze, M. W. (2015) The RNA-binding proteomes from yeast to man harbour conserved enigmRBPs. *Nat. Commun.* **6**, 10127 CrossRef Medline

54. Howard, M. J., Lim, W. H., Fierke, C. A., and Koutmos, M. (2012) Mitochondrial ribonuclease P structure provides insight into the evolution of catalytic strategies for precursor-tRNA 5' processing. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 16149–16154 CrossRef Medline

55. Howard, M. J., Liu, X., Lim, W. H., Klemm, B. P., Fierke, C. A., Koutmos, M., and Engelke, D. R. (2013) RNase P enzymes Divergent scaffolds for a conserved biological reaction Michael. *RNA Biol.* **10**, 909–914 CrossRef Medline

56. Sheldrick, G. M. (2008) A short history of SHELX. *Acta Crystallogr. Sect. A Found. Crystallogr.* **64**, 112–122 CrossRef Medline

57. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 CrossRef Medline

58. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 CrossRef Medline

59. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., et al. (2011) Overview of the CCP4 suite and current developments. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 235–242 CrossRef Medline

50. Vagin, A. A., Steiner, R. A., Lebedev, A. A., Potterson, L., McNicholas, S., Long, F., and Murshudov, G. N. (2004) REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2184–2195 CrossRef Medline

51. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132 CrossRef Medline

52. Niesen, F. H., Berglund, H., and Vedadi, M. (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. *Nat. Protoc.* **2**, 2212–2221 CrossRef Medline

53. Petoukhov, M. V., and Svergun, D. I. (2015) Ambiguity assessment of small-angle scattering curves from monodisperse systems. *Acta Crystallogr. D Biol. Crystallogr.* **71**, 1051–1058 CrossRef Medline

54. Fischer, H., de Oliveira Neto, M., Napolitano, H. B., Polikarpov, I., and Craievich, A. F. (2010) Determination of the molecular weight of proteins in solution from a single small-angle X-ray scattering measurement on a relative scale. *J. Appl. Crystallogr.* **43**, 101–109 CrossRef
Structural insight into the human mitochondrial tRNA purine N1-methyltransferase and ribonuclease P complexes
Stephanie Oerum, Martine Roovers, Robert P. Rambo, Jola Kopec, Henry J. Bailey, Fiona Fitzpatrick, Joseph A. Newman, William G. Newman, Albert Amberger, Johannes Zschocke, Louis Droogmans, Udo Oppermann and Wyatt W. Yue

J. Biol. Chem. 2018, 293:12862-12876.
doi: 10.1074/jbc.RA117.001286 originally published online June 7, 2018

Access the most updated version of this article at doi: 10.1074/jbc.RA117.001286

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 66 references, 9 of which can be accessed free at http://www.jbc.org/content/293/33/12862.full.html#ref-list-1